TY - JOUR
T1 - Gene amplification and proliferative kinetics in relation to prognosis of patients with gastric carcinoma
AU - Amadori, Dino
AU - Maltoni, Marco
AU - Volpi, Annalisa
AU - Nanni, Oriana
AU - Scarpi, Emanuela
AU - Renault, Beatrice
AU - Pellegata, Natalia S.
AU - Gaudio, Michele
AU - Magni, Enrico
AU - Ranzani, Guglielmina N.
PY - 1997/1/15
Y1 - 1997/1/15
N2 - BACKGROUND. The differences in survival of gastric carcinoma patients who have identical clinical or pathologic stages prompted the authors to investigate the prognostic significance of biologic features that are known to affect the clinical aggressiveness of other tumor types. METHODS. One hundred twenty-four tumor samples from patients who had received radical or palliative surgery were analyzed for c-myc, c-K-ras, hst, and c-erb B-2 gene amplification by means of the Southern blot technique. Of these tumors, 70 were also examined for cell kinetics by means of the thymidine labeling index (TLI). RESULTS. The analysis of associations between gene amplification and the anatomicopathologic variables (TNM classification, site of tumor, and histology) showed that amplification represents a late event in the natural history of gastric carcinoma. Gene amplification showed a slight, statistically insignificant, negative impact on overall survival (OS) (P = 0.09). Amplification of c-erb B-2 correlated in a statistically significant way with reduced OS (P = 0.03). Cox multiple regression analysis revealed that neither c-erb B 2 amplification nor TLI had prognostic significance in relation to OS. CONCLUSIONS. These data indicate that amplification of the examined oncogenes did not reveal a new independent prognostic factor for patients with gastric carcinoma. However, the authors' results did show a strong correlation between gene amplification and tumor progression, which warrants further study involving larger series of patients. At the same time, the TLI results underlined the need to identify the moist suitable biologic material for use in the estimation of proliferative indexes in gastric carcinoma.
AB - BACKGROUND. The differences in survival of gastric carcinoma patients who have identical clinical or pathologic stages prompted the authors to investigate the prognostic significance of biologic features that are known to affect the clinical aggressiveness of other tumor types. METHODS. One hundred twenty-four tumor samples from patients who had received radical or palliative surgery were analyzed for c-myc, c-K-ras, hst, and c-erb B-2 gene amplification by means of the Southern blot technique. Of these tumors, 70 were also examined for cell kinetics by means of the thymidine labeling index (TLI). RESULTS. The analysis of associations between gene amplification and the anatomicopathologic variables (TNM classification, site of tumor, and histology) showed that amplification represents a late event in the natural history of gastric carcinoma. Gene amplification showed a slight, statistically insignificant, negative impact on overall survival (OS) (P = 0.09). Amplification of c-erb B-2 correlated in a statistically significant way with reduced OS (P = 0.03). Cox multiple regression analysis revealed that neither c-erb B 2 amplification nor TLI had prognostic significance in relation to OS. CONCLUSIONS. These data indicate that amplification of the examined oncogenes did not reveal a new independent prognostic factor for patients with gastric carcinoma. However, the authors' results did show a strong correlation between gene amplification and tumor progression, which warrants further study involving larger series of patients. At the same time, the TLI results underlined the need to identify the moist suitable biologic material for use in the estimation of proliferative indexes in gastric carcinoma.
KW - cell kinetics
KW - gastric cancer
KW - oncogene amplification
KW - prognosis
UR - http://www.scopus.com/inward/record.url?scp=0031022945&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031022945&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1097-0142(19970115)79:2<226::AID-CNCR5>3.0.CO;2-I
DO - 10.1002/(SICI)1097-0142(19970115)79:2<226::AID-CNCR5>3.0.CO;2-I
M3 - Article
C2 - 9010095
AN - SCOPUS:0031022945
VL - 79
SP - 226
EP - 232
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 2
ER -